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A B S T R A C T
Objectives: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been shown to be
eﬀective for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) in clinical trials.
However, there is a lack of data from routine clinical practice. This study determined treatment and outcomes in
patients with EGFR mutation-positive NSCLC treated in a real world setting.
Materials and methods: Clinical characteristics, information about NSCLC treatment regimens and survival out-
comes data were obtained retrospectively from 17 medical centers across Japan. In addition to overall survival
(OS), subgroup analyses were conducted based on ﬁrst- and second-line treatments and combinations, and for
patients who had survived>5 years from initiation of ﬁrst-line treatment.
Results: The full analysis set comprised 1656 patients (mean 67 years, 80.6% with performance status 0 or 1).
Median follow-up was 29.5 months and median OS was 29.7 months; 3- and 5-year survival rates were 41.2%
and 21.5%, respectively. Signiﬁcant predictors of OS were younger age, no smoking history, histological diag-
nosis of adenocarcinoma, less advanced clinical stage, good performance status and major EGFR-activating
mutation. Despite some imbalances in baseline characteristics, patients who received ﬁrst-line chemotherapy
had numerically higher 5-year survival rates than those who received ﬁrst-line EGFR-TKIs.
Conclusions: This large, long-term analysis of EGFR mutation-positive NSCLC patients provides useful in-
formation about treatment outcomes in clinical practice. Updated analyses are required to determine real world
outcomes for NSCLC patients treated with the latest available agents, including immunotherapies.
1. Introduction
Previous clinical studies, including several phase III trials, have
shown that epidermal growth factor receptor (EGFR)-tyrosine kinase
inhibitors (TKIs) are superior to chemotherapy in terms of progression-
free survival and objective response rate [1–8]. Based on these data,
EGFR-TKIs are now recommended as ﬁrst-line treatment for EGFR
mutation-positive NSCLC by major international and Japanese clinical
guidelines [9–11]. However, there are many patient groups en-
countered in clinical practice that do not meet the stringent inclusion
criteria required for participation in clinical trials. Therefore, the ef-
fectiveness of EGFR-TKIs in patients treated in the real world setting
remains unclear. Furthermore, although some EGFR mutation-positive
NSCLC patients survive over the long term, most clinical trials do not
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include detailed data on long-term survivors because of relatively short
follow-up periods.
There is no doubt that EGFR-TKIs are important therapeutic agents
for the treatment of EGFR mutation-positive NSCLC patients. However,
there is uncertainty around how chemotherapies are used and for how
long. In addition, the contribution of diﬀerent chemotherapies to
overall survival is not clearly understood. To address these important
clinical questions, this study determined treatment and outcomes in a
large group of patients with EGFRmutation-positive NSCLC managed in
a real world clinical setting.
2. Materials and methods
This retrospective study was conducted at 17 medical centers across
Japan (clinical trial registration: NCT02475720). The study was ap-
proved by the institutional review boards or ethics review boards at
each site and conducted in accordance with the Declaration of Helsinki.
This research was deﬁned as a study without human samples by the
Japanese guidelines presented by the Ministry of Health, Labour and
Welfare: ‘Ethical guidelines for epidemiologic research, dated 17 June
2002′, ‘Ethical guidelines for clinical research, dated 30 July 2003′ and
‘Ethical guidelines for medical research involving human subjects,
dated 22 December 2014′. Therefore, written informed consent was not
required.
2.1. Patients
All patients had EGFR gene mutation-positive NSCLC diagnosed by
histology or cytology samples and started ﬁrst-line treatment between
January 2008 and December 2012. Those treated with agents that were
not approved in Japan as of 31 December 2014 were excluded from the
current analysis.
2.2. Data collection
Clinical data were collected from the medical records of each pa-
tient. This included patient characteristics (date of NSCLC diagnosis,
sex, age at the time of diagnosis, histological diagnosis, clinical staging
at initial diagnosis, distant metastasis organ, Eastern Cooperative
Oncology Group [ECOG] performance status [PS], smoking history,
type of EGFR mutation); survival data (status as at the end of December
2015, date of death or date of last follow-up); and information about
NSCLC treatments (regimens, date of ﬁrst dose, date of last dose, PS at
the start of each treatment regimen, best response for each treatment
regimen, reason for treatment discontinuation or change of treatment
regimen, presence or absence of radiotherapy and target region for
radiotherapy, presence or absence of brain metastasis, date of pro-
gressive disease [PD]). PD was deﬁned according to Response
Evaluation Criteria in Solid Tumours (RECIST) version 1.1 or clinical
PD.
2.3. Grouping of treatment regimens
For analysis of treatments, regimens were categorized into the fol-
lowing three groups: 1) EGFR-TKIs (EGFR-TKI as monotherapy or in
combination with other agents), 2) chemotherapy (platinum- or non-
platinum-based combination chemotherapy [excluding combinations
including EGFR-TKIs]) and 3) other (any treatment that did not fall into
the other two groups, e.g., bevacizumab monotherapy).
2.4. Statistical analysis
Overall survival (OS) was deﬁned as the interval from the date of
ﬁrst dose of ﬁrst-line treatment until the date of death. Patients lost to
follow-up were censored at the date they were last known to be alive.
Time-to-event data were calculated as median values with 95%
conﬁdence intervals (CI). Survival analysis was performed using the
Kaplan–Meier method.
The inﬂuence of patient characteristics on OS was assessed using
univariate and multivariate Cox regression analysis. For the multi-
variate full model, which included all items as explanatory variables,
variants were selected by the backward elimination method. Analyzed
factors were year of diagnosis, year ﬁrst-line treatment was started, sex,
age, histological diagnosis, EGFR mutation type, clinical stage, PS,
smoking history and type of ﬁrst-line treatment. In addition, a post-hoc
analysis was conducted in the 799 patients who started ﬁrst-line
treatment before 31 December 2010 (i.e., prior to> 5 years before the
data cut oﬀ)—multiple logistic regression analysis was used to compare
5-year survivors in this group with other patients.
Average cumulative periods of three treatment options (EGFR-TKIs,
chemotherapy and no treatment [drug holidays]) were calculated and
diﬀerences for each period between patients who received ﬁrst-line
EGFR-TKIs compared with ﬁrst-line chemotherapy were assessed using
the Wilcoxon test.
Median survival time and 5-year survival rate by ﬁrst- and second-
line treatment sequences were calculated in patients for whom suﬃ-
cient clinical data on ﬁrst- and second-line treatment were available. In
an exploratory analysis, the inverse probability of treatment weighting
using the propensity score calculated from data before, during and after
ﬁrst-line treatment was determined and OS rates for patients in each
group were estimated.
3. Results
3.1. Patient characteristics and EGFR-TKI treatment
A total of 1660 EGFR mutation-positive advanced NSCLC patients
were enrolled in the study. After excluding four ineligible patients,
1656 patients were included in the full analysis set (FAS) (Fig. 1).
Baseline demographics and clinical characteristics of included patients
are summarized in Table 1. The number of patients who received
second-line, third-line, and fourth-line therapy were 1192 (72.0%), 800
(48.3%), and 490 (29.6%), respectively. Of the 1656 patients, 1608
(97.1%) received at least one EGFR-TKI in any treatment line. The ﬁrst
administered EGFR-TKI was geﬁtinib in 1347 (81.3%) patients, erlo-
tinib in 245 (14.8%) patients, and afatinib in 16 (1.0%) patients.
3.2. Overall survival
Median follow-up was 29.5 months, and median OS was 29.7
months (95% CI 28.1–31.4). From the start of ﬁrst-line treatment, 3-
and 5-year survival rates were 41.2% (95% CI 38.7–43.7) and 21.5%
(95% CI 19.1–23.9), respectively (Supplementary Fig. S1). In patients
with stage IV disease (n=1104), median OS was 25.2 months (95% CI
23.8–26.4), and 3- and 5-year survival rates from the start of ﬁrst-line
treatment were 32.0% (95% CI 29.1–35.0) and 13.8% (95% CI
11.4–16.5), respectively. On multivariate ﬁnal model Cox regression
analysis, younger age (< 75 years), no smoking history, histological
diagnosis of adenocarcinoma, less advanced clinical stage, good PS and
major EGFR-activating mutation were identiﬁed as signiﬁcant pre-
dictors of OS (Table 2). The mean survival times of patients with exon
19 deletion (n=814) and the L858R mutation (n= 666) were 31.87
and 28.27 months, respectively (data not shown).
3.3. Overall survival by treatment sequences
A total of 1055 patients were included in the analysis of OS by the
sequence of ﬁrst- and second-line treatment (see Fig. 1 for details of
exclusions). In patients treated with ﬁrst-line EGFR-TKIs and second-
line chemotherapy, 87.8% (295/336) changed treatment because of
disease progression, and 74.1% (249/336) received platinum-based
combination chemotherapy as second-line treatment. In the group
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treated with EGFR-TKIs for ﬁrst- and second-line therapy, 63.7% (142/
223) switched treatment because of disease progression. The most
common EGFR-TKI switch was from geﬁtinib to erlotinib (78.9%, 176/
223). No patients received a third-generation EGFR-TKI because none
were authorized during the study period. Among patients treated with
chemotherapy in both ﬁrst- and second-line, 69.5% (41/59) went on to
receive EGFR-TKIs as third-line treatment. Median survival times were
similar for the diﬀerent patient groups based on ﬁrst- and second-line
treatment sequences (Fig. 2). Five-year survival rates were higher in
patients who received ﬁrst-line chemotherapy than those who received
ﬁrst-line EGFR-TKIs (Fig. 2), although there were several imbalances in
characteristics among patient groups (Supplementary Table S1).
In the post-hoc analysis comparing patients with> 5 years’ follow-
up, ﬁrst-line treatment with chemotherapy, female sex, less advanced
clinical stage and good PS were signiﬁcantly associated with survival
for more than 5 years (Table 3).
3.4. Treatment periods analysis
Additionally, the treatment period was analyzed by categorizing
patients into two groups based on the type of ﬁrst-line therapy. The
average cumulative period of EGFR-TKIs, chemotherapy and no treat-
ment (drug holidays) were calculated and compared between patients
who received ﬁrst-line EGFR-TKIs versus ﬁrst-line chemotherapy. The
average EGFR-TKI treatment period was signiﬁcantly longer, and
average chemotherapy and “no treatment” periods signiﬁcantly shorter
in patients who received ﬁrst-line EGFR-TKIs compared with ﬁrst-line
chemotherapy (Table 4).
4. Discussion
To the best of our knowledge, this is the largest real world survival
analysis of EGFR mutation-positive NSCLC patients (1140 deaths con-
ﬁrmed in 1656 patients). In addition, long-term follow-up data were
available (median 25.5 months, maximum 96 months) Furthermore,
Enrolled patients (n = 1660)
Excluded patients (n = 4)
• Started first-line treatment in 2013 (n = 1)
• Unknown date of start of first-line treatment (n = 1)
• Unknown date of death (n = 2)
Full analysis set (n = 1656)
• Alive (n = 256)
• Deceased (n = 1140)
• Lost to follow-up (n = 260)
Excluded patients (n = 601)
• Treatment other than EGFR-TKI and chemotherapy in first-
or second-line treatment (n = 12)
• Insufficient data at the start of first-line treatment (n = 97)
• Insufficient data during first-line treatment and at the start of 
second-line treatment (n = 125)
• Did not receive second-line treatment (n = 367)
Patients for first- and second-
line treatment sequence 
analysis (n = 1055)
Fig. 1. Study ﬂow diagram.
Table 1
Patient characteristics.
Characteristics All (N= 1656,
100.0%)
Age (at start of ﬁrst
treatment: years)
Median (range) 67.0 (27–97)
Sex Male 583 (35.2%)
Female 1073 (64.8%)
Smoking history Smoker 645 (38.9%)
Non-smoker 981 (59.2%)
Unknown 30 (1.8%)
Histology Adenocarcinoma 1576 (95.2%)
Others 80 (4.8%)
Clinical stage IV 1104 (66.7%)
IIIB 125 (7.5%)
Post-operative recurrence 427 (25.8%)










Presence of brain metastasis Yes 489 (29.5%)
No/Unknown 1167 (70.5%)
Number of metastatic organs 0 288 (17.4%)
1 726 (43.8%)
2 353 (21.3%)
More than 3 289 (17.5%)
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this analysis included a large proportion of frail patients who would
likely have been excluded from clinical trials (e.g., those with poor PS).
The inclusion of patients from a large number of centers means that the
results are applicable across a range of clinical practice settings.
Although the current standard ﬁrst-line treatment for EGFR muta-
tion-positive patients is EGFR-TKI monotherapy, approximately one-
third of patients included in our study actually received chemotherapy
as ﬁrst-line treatment. Of these, approximately 60% had started ﬁrst-
line treatment by the end of 2010. The results of the majority of the
randomized controlled phase III trials showing the superiority of EGFR-
TKIs versus chemotherapy with respect to progression-free survival in
EGFR mutation-positive NSCLC patients were reported later than 2010,
and ﬁrst-line EGFR-TKI treatment only became standard after that. This
is likely to be the reason so many patients in our study received ﬁrst-
line chemotherapy.
Our data showed that 5-year survival rates for patients treated with
ﬁrst-line chemotherapy were numerically higher than those treated
with ﬁrst-line EGFR-TKIs. Even after adjustment for imbalances of
baseline patient characteristics by multivariate analysis, ﬁrst-line
treatment of chemotherapy was associated with>5-year survival
(Table 3). This could be for several potential reasons. First, transition
rates from ﬁrst-line to second-line were diﬀerent between patients who
received initial therapy with EGFR-TKIs compared with chemotherapy:
93% of those who received ﬁrst-line chemotherapy went on to receive
second-line treatment, but< 60% of those initially treated with EGFR-
TKIs received second-line treatment. Furthermore, over half of ﬁrst-line
EGFR-TKI-treated patients did not receive chemotherapy at any time
throughout their treatment. As a result, the duration of chemotherapy
treatment was signiﬁcantly shorter in patients who received ﬁrst-line
EGFR-TKIs compared with those who had ﬁrst-line chemotherapy. This
suggests that many patients who received ﬁrst-line EGFR-TKIs may
have missed the opportunity to receive chemotherapy because they
continued taking EGFR-TKIs for too long after disease progression. As
documented in several studies [12–14], chemotherapy is also a poten-
tial option for EGFR mutation-positive NSCLC patients after ﬁrst-line
EGFR-TKI treatment. Therefore, chemotherapy should be considered as
an option following disease progression after ﬁrst-line EGFR-TKI
treatment, although speciﬁc treatments targeting the diﬀerent me-
chanisms of drug resistance that arise are desirable [15].
Although no patients received a third-generation EGFR-TKI in the
present study, the third-generation EGFR-TKI osimertinib is currently
considered as a ﬁrst choice for patients who carry the EGFR T790M
mutation at disease progression after ﬁrst-line EGFR-TKI treatment
[16]. Considering these points, chemotherapy should be recommended
as third-line treatment, immediately after osimertinib, in patients who
carry the EGFR T790M mutation at disease progression after ﬁrst-line
EGFR-TKI therapy.
To explore the diﬀerences in overall survival among patient groups
categorized by ﬁrst-line and second-line treatment sequences, it was
necessary to consider the imbalances of patient background among
each group shown in Supplementary Table S1. The inverse probability
of treatment weighting using the propensity score calculated from data
before, during, and after ﬁrst-line treatment was performed and overall
survival times of patients in each group were estimated. However, no
diﬀerences were observed among the point estimations of OS for each
group (Supplementary Table S2).
In conclusion, EGFR mutation-positive NSCLC patients managed in
real world clinical practice had long OS durations. Our ﬁndings showed










0 12 24 36 48
Fig. 2. Kaplan-Meier Curve, median survival time and 5-year survival rate in patient
subgroups based on ﬁrst- and second-line treatment sequences.
Table 3
Multiple logistic regression analysis comparing patient survival 5 years after the initiation of ﬁrst-line treatment.
Item Category Univariate Model Multivariate Full Model, Backward Elimination p < 0.05
Odds Ratio [Item p Value] Odds Ratio [Item p Value]
Point Estimation 95% CI Category p Value Point Estimation 95% CI Category p Value
Sex Male Reference – – Reference – –
Female 1.284 (0.848, 1.943) 0.237 1.819 (1.149, 2.881) 0.011
Clinical stage IV Reference – [< 0.001] Reference – [< 0.001]
IIIB 2.633 (1.426, 4.862) 0.002 2.153 (1.136, 4.081) 0.019
Post-operative recurrence 4.570 (2.966, 7.040) < 0.001 4.459 (2.802, 7.094) <0.001
PS 0 Reference – [< 0.001] Reference – [< 0.001]
1 0.396 (0.263, 0.598) < 0.001 0.449 (0.292, 0.689) <0.001
2, 3, 4 0.028 (0.004, 0.200) < 0.001 0.039 (0.005, 0.290) 0.001
First-line treatment EGFR-TKIs Reference – – Reference – –
Chemotherapy 1.516 (1.029, 2.235) 0.036 1.854 (1.190, 2.888) 0.006
Factors included in the model were year of diagnosis, year ﬁrst-line treatment was started, sex, age, histological diagnosis, EGFR mutation type, clinical stage, performance status,
smoking history, and type of ﬁrst-line treatment. Chemotherapy, platinum-based or non-platinum-based chemotherapy.
Table 4




EGFR-TKIs Chemotherapy Wilcoxon Test
EGFR-TKIs 17.9 15.9 p < 0.001
Chemotherapy 2.9 7.3 p < 0.001
No treatment (including drug
holidays)
4.6 8.7 p < 0.001
The patients whose data on treatment period were not suﬃcient and who received
treatment other than EGFR-TKIs and chemotherapy were excluded (ﬁve patients of ﬁrst-
line EGFR-TKIs group, 10 patients of ﬁrst-line chemotherapy group). Chemotherapy,
platinum-based or non-platinum-based chemotherapy; EGFR-TKIs, monotherapy with an
epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) or combination
therapy including an EGFR-TKI.
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after EGFR-TKI treatment failure in order to maximize survival time in
these patients. Since this study was conducted, a number of new
treatment options have become available, including third-generation
EGFR-TKIs and immune checkpoint inhibitors, which have further im-
proved outcomes in EGFRmutation-positive NSCLC patients. Additional
real world analyses are required to more clearly deﬁne the impact of
these new agents on OS in the routine clinical practice setting.
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